Cargando…

Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center

PURPOSE: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce. PATIENTS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefner, Jochen, Berberich, Sara, Lanvers, Elena, Sanning, Maria, Steimer, Ann-Kathrin, Kunzmann, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159803/
https://www.ncbi.nlm.nih.gov/pubmed/30288028
http://dx.doi.org/10.2147/PPA.S169354
_version_ 1783358660410343424
author Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
author_facet Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
author_sort Hefner, Jochen
collection PubMed
description PURPOSE: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce. PATIENTS AND METHODS: Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient–Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients’ perceptions and behavior. Medical data were extracted from the charts. RESULTS: Non-adherence was reported by 20% of the 64 participants. The perceived quality of the patient–doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808–1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95% CI=1.090–1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95% CI=1.010–1.551) were predictors of adherence and the quality of the patient–doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life. CONCLUSIONS: In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients’ informational needs as well as the associations of patients’ beliefs and satisfaction about the information received suggest a benefit from a trustful patient–doctor relationship.
format Online
Article
Text
id pubmed-6159803
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61598032018-10-04 Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center Hefner, Jochen Berberich, Sara Lanvers, Elena Sanning, Maria Steimer, Ann-Kathrin Kunzmann, Volker Patient Prefer Adherence Original Research PURPOSE: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce. PATIENTS AND METHODS: Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient–Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients’ perceptions and behavior. Medical data were extracted from the charts. RESULTS: Non-adherence was reported by 20% of the 64 participants. The perceived quality of the patient–doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808–1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95% CI=1.090–1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95% CI=1.010–1.551) were predictors of adherence and the quality of the patient–doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life. CONCLUSIONS: In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients’ informational needs as well as the associations of patients’ beliefs and satisfaction about the information received suggest a benefit from a trustful patient–doctor relationship. Dove Medical Press 2018-09-21 /pmc/articles/PMC6159803/ /pubmed/30288028 http://dx.doi.org/10.2147/PPA.S169354 Text en © 2018 Hefner et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hefner, Jochen
Berberich, Sara
Lanvers, Elena
Sanning, Maria
Steimer, Ann-Kathrin
Kunzmann, Volker
Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title_full Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title_fullStr Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title_full_unstemmed Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title_short Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
title_sort patient–doctor relationship and adherence to capecitabine in outpatients of a german comprehensive cancer center
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159803/
https://www.ncbi.nlm.nih.gov/pubmed/30288028
http://dx.doi.org/10.2147/PPA.S169354
work_keys_str_mv AT hefnerjochen patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter
AT berberichsara patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter
AT lanverselena patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter
AT sanningmaria patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter
AT steimerannkathrin patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter
AT kunzmannvolker patientdoctorrelationshipandadherencetocapecitabineinoutpatientsofagermancomprehensivecancercenter